BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37950840)

  • 1. Synergistic effect of the verapamil and amphotericin B against Cryptococcus neoformans.
    Pereira TC; do Carmo PHF; de Menezes RT; de Oliveira HC; de Oliveira LD; Junqueira JC; Scorzoni L
    Folia Microbiol (Praha); 2023 Dec; 68(6):999-1004. PubMed ID: 37950840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adaptation to Fluconazole via Aneuploidy Enables Cross-Adaptation to Amphotericin B and Flucytosine in Cryptococcus neoformans.
    Yang F; Gritsenko V; Lu H; Zhen C; Gao L; Berman J; Jiang YY
    Microbiol Spectr; 2021 Oct; 9(2):e0072321. PubMed ID: 34585947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic effect of pyrvinium pamoate and posaconazole against
    Li Y; Li S; Chen M; Xiao J; Fang H
    Front Cell Infect Microbiol; 2022; 12():1074903. PubMed ID: 36569209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Off-Patent Drugs That Show Synergism with Amphotericin B or That Present Antifungal Action against Cryptococcus neoformans and
    Rossi SA; de Oliveira HC; Agreda-Mellon D; Lucio J; Mendes-Giannini MJS; García-Cambero JP; Zaragoza O
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.
    Schwarz P; Dromer F; Lortholary O; Dannaoui E
    Antimicrob Agents Chemother; 2006 Jan; 50(1):113-20. PubMed ID: 16377675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of antifungal combination against Cryptococcus spp.
    Reichert-Lima F; Busso-Lopes AF; Lyra L; Peron IH; Taguchi H; Mikami Y; Kamei K; Moretti ML; Schreiber AZ
    Mycoses; 2016 Sep; 59(9):585-93. PubMed ID: 27135278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the relationship between drug susceptibility of Cryptococcus neoformans isolates and mortality in HIV-negative cryptococcal meningitis.
    Su Z; Wei H; Liu J; Li C; Xu Z; Yuan D; Dai K; Peng F; Jiang Y
    J Glob Antimicrob Resist; 2024 Mar; 36():167-174. PubMed ID: 38141953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy.
    Rodero L; Córdoba S; Cahn P; Hochenfellner F; Davel G; Canteros C; Kaufman S; Guelfand L
    J Antimicrob Chemother; 2000 Feb; 45(2):239-42. PubMed ID: 10660509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
    Nishikawa MM; Almeida-Paes R; Brito-Santos F; Nascimento CR; Fialho MM; Trilles L; Morales BP; da Silva SA; Santos W; Santos LO; Fortes ST; Cardarelli-Leite P; Lázera MDS
    Med Mycol; 2019 Oct; 57(7):864-873. PubMed ID: 30657975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of iron chelators on growth and expression of iron-related genes of Cryptococcus species.
    Chayakulkeeree M; Tangkoskul T; Waywa D; Tiengrim S; Pati N; Thamlikitkul V
    J Mycol Med; 2020 Apr; 30(1):100905. PubMed ID: 31706700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions between antifungals and everolimus against
    Liang P; Song J; Liu Q
    Front Cell Infect Microbiol; 2023; 13():1131641. PubMed ID: 37026056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro interaction of antifungal and antibacterial drugs against Cryptococcus neoformans var. grubii before and after capsular induction.
    Rossato L; Loreto ÉS; Venturini TP; Azevedo MI; Weiblen C; Botton SA; Santurio JM; Alves SH
    Med Mycol; 2015 Nov; 53(8):885-9. PubMed ID: 26333356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Oral Encochleated Amphotericin B in a Mouse Model of Cryptococcal Meningoencephalitis.
    Lu R; Hollingsworth C; Qiu J; Wang A; Hughes E; Xin X; Konrath KM; Elsegeiny W; Park YD; Atakulu L; Craft JC; Tramont EC; Mannino R; Williamson PR
    mBio; 2019 May; 10(3):. PubMed ID: 31138748
    [No Abstract]   [Full Text] [Related]  

  • 14. Interactions between triazoles and amphotericin B against Cryptococcus neoformans.
    Barchiesi F; Schimizzi AM; Caselli F; Novelli A; Fallani S; Giannini D; Arzeni D; Di Cesare S; Di Francesco LF; Fortuna M; Giacometti A; Carle F; Mazzei T; Scalise G
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2435-41. PubMed ID: 10952592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro synergistic effects of fluoxetine and paroxetine in combination with amphotericin B against Cryptococcus neoformans.
    Pereira TC; de Menezes RT; de Oliveira HC; de Oliveira LD; Scorzoni L
    Pathog Dis; 2021 Feb; 79(2):. PubMed ID: 33417701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro synergistic effect of minocycline combined with antifungals against Cryptococcus neoformans.
    Tan L; Shi H; Chen M; Wang Z; Yao Z; Sun Y
    J Mycol Med; 2022 Mar; 32(1):101227. PubMed ID: 34800920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimalarials and amphotericin B interact synergistically and are new options to treat cryptococcosis.
    Freitas GJC; Ribeiro NQ; Gouveia-Eufrasio L; Emidio ECP; Guimarães GM; César IC; Paixão TA; Oliveira JBS; Caza M; Kronstad JW; Santos DA
    Int J Antimicrob Agents; 2023 Jul; 62(1):106807. PubMed ID: 37030471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro synergistic effects of chlorpromazine and sertraline in combination with amphotericin B against Cryptococcus neoformans var. grubii.
    Rossato L; Loreto ÉS; Zanette RA; Chassot F; Santurio JM; Alves SH
    Folia Microbiol (Praha); 2016 Sep; 61(5):399-403. PubMed ID: 26847460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility of clinical isolates of Cryptococcus neoformans to amphotericin B using time-kill methodology.
    Pappalardo MC; Szeszs MW; Martins MA; Baceti LB; Bonfietti LX; Purisco SU; Baez AA; Melhem MS
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):146-51. PubMed ID: 19345042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of Cryptococcus neoformans.
    Hai TP; Van AD; Ngan NTT; Nhat LTH; Lan NPH; Vinh Chau NV; Thwaites GE; Krysan D; Day JN
    Mycoses; 2019 Sep; 62(9):818-825. PubMed ID: 31173410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.